Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cancer Research Technology Ltd. is currently managing 2 pending office actions within the Biotechnology and Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners, allowing for different viewpoints during the examination process. Both actions are situated within 1 distinct art unit, indicating that the technology remains within a specific pharmaceutical sub-field. The presence of 2 pending office actions suggests an effort to secure intellectual property in this technical domain.
The busiest examiner, BLACKSTEN, SYDNEY LYNN, is responsible for 1 pending office action. With the 2 pending office actions split between two different examiners, the company must navigate two individual examination styles. This requires a coordinated approach to ensure that the prosecution of both matters remains consistent, especially since they are being reviewed within the same art unit. Practitioners should monitor both examiners to identify any common technical hurdles in the Biotechnology and Pharmaceuticals space. The use of 2 distinct examiners provides a level of distribution in the company's current patent strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOORE, SUSANNA | 1 | 68.0% | +31.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705194 | TRICYCLIC HETEROCYCLES | MOORE, SUSANNA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705194 | TRICYCLIC HETEROCYCLES | MOORE, SUSANNA | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18705194 | TRICYCLIC HETEROCYCLES | MOORE, SUSANNA | 1624 | §102§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCancer Research Technology Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Susanna Moore has the most, with 1 of Cancer Research Technology Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.